All about NASH: disease biology, targets, and opportunities on the road to NASH drugs
Acta Pharmacol Sin
.
2022 May;43(5):1101-1102.
doi: 10.1038/s41401-022-00900-y.
Epub 2022 Apr 4.
Authors
H Eric Xu
1
,
Jin-Song Guo
2
Affiliations
1
Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. eric.xu@simm.ac.cn.
2
DrugTimes Team, BioSeed (Shanghai) Biotechnology Co., Ltd., Shanghai, 201203, China. jinsong.guo@drugtimes.cn.
PMID:
35379932
PMCID:
PMC9061727
DOI:
10.1038/s41401-022-00900-y
No abstract available
Publication types
Editorial
MeSH terms
Biology
Humans
Non-alcoholic Fatty Liver Disease* / drug therapy